RCUSのニュース
Arcus Biosciences (NYSE:RCUS) Trading Up 5% 2023/04/02 07:36:45 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) was up 5% during mid-day trading on Friday . The stock traded as high as $18.34 and last traded at $18.33. Approximately 37,462 shares traded hands during trading, a decline of 97% from the average daily volume of 1,090,225 shares. The stock had previously closed at $17.46. Wall […]
Arcus Biosciences (NYSE:RCUS) Trading 5% Higher 2023/04/02 07:00:42 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating)’s share price traded up 5% during trading on Friday . The company traded as high as $18.34 and last traded at $18.33. 37,462 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,090,225 shares. The stock had previously closed at $17.46. […]
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results 2023/03/23 04:58:07 Seeking Alpha
Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study. See why RCUS stock is a Buy.
Arcus Biosciences Files Mixed Shelf 2023/03/01 11:01:01 Investing.com
https://www.investing.com/news/assorted/arcus-biosciences-files-mixed-shelf-432SI-3018317
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update 2023/02/28 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple c
Arcus Biosciences (NYSE:RCUS) Trading Up 5% 2023/04/02 07:36:45 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) was up 5% during mid-day trading on Friday . The stock traded as high as $18.34 and last traded at $18.33. Approximately 37,462 shares traded hands during trading, a decline of 97% from the average daily volume of 1,090,225 shares. The stock had previously closed at $17.46. Wall […]
Arcus Biosciences (NYSE:RCUS) Trading 5% Higher 2023/04/02 07:00:42 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating)’s share price traded up 5% during trading on Friday . The company traded as high as $18.34 and last traded at $18.33. 37,462 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,090,225 shares. The stock had previously closed at $17.46. […]
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results 2023/03/23 04:58:07 Seeking Alpha
Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study. See why RCUS stock is a Buy.
Arcus Biosciences Files Mixed Shelf 2023/03/01 11:01:01 Investing.com
https://www.investing.com/news/assorted/arcus-biosciences-files-mixed-shelf-432SI-3018317
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update 2023/02/28 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple c
Arcus Biosciences (NYSE:RCUS) Trading Up 5% 2023/04/02 07:36:45 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) was up 5% during mid-day trading on Friday . The stock traded as high as $18.34 and last traded at $18.33. Approximately 37,462 shares traded hands during trading, a decline of 97% from the average daily volume of 1,090,225 shares. The stock had previously closed at $17.46. Wall […]
Arcus Biosciences (NYSE:RCUS) Trading 5% Higher 2023/04/02 07:00:42 The AM Reporter
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating)’s share price traded up 5% during trading on Friday . The company traded as high as $18.34 and last traded at $18.33. 37,462 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 1,090,225 shares. The stock had previously closed at $17.46. […]
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results 2023/03/23 04:58:07 Seeking Alpha
Arcus recently announced positive results from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study. See why RCUS stock is a Buy.
Arcus Biosciences Files Mixed Shelf 2023/03/01 11:01:01 Investing.com
https://www.investing.com/news/assorted/arcus-biosciences-files-mixed-shelf-432SI-3018317
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update 2023/02/28 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth-quarter and full-year ended December 31, 2022 and provided a pipeline update on its six clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple c